Lexaria Bioscience Corp.
LEXX, LEXXWHealthcare · Healthcare · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 | $384,543 |
| Operating income | −$11.9M | −$5.8M | −$6.5M | −$6.6M | −$5.7M | — |
| Net income | −$11.9M | −$5.8M | −$6.7M | −$7.3M | −$4.0M | −$4.1M |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M | $2.8M |
| Total liabilities | $1.6M | $1.2M | $403,908 | $201,437 | $203,265 | $345,980 |
| Equity | $3.0M | $8.0M | $3.0M | $7.9M | $13.3M | $2.5M |
| EPS (diluted) | $-0.66 | $-0.47 | $-1.01 | — | — | — |
| Shares out. | 22.2M | 17.5M | 10.3M | 6.0M | 5.7M | 90.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1683.0%
- Net margin
- −1686.0%
- Return on equity
- −398.1%
- Return on assets
- −285.1%
- Return on capital (ROCE)
- −443.0%
- Liabilities / assets
- 37.7%
- Debt / equity
- 0.53×
- Book value / share
- $0.13
- Revenue growth (YoY)
- 52.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -63.57distress
- Accruals / assets
- −34.8%clean
- Beneish M-Score
- -3.51normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Dec 1, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bunka ChristopherDirector | Mar 17, 2026 | Gift | 100,000 | $0.00 |
| Bunka ChristopherDirector | Jul 29, 2025 | Buy | 15,600 | $0.92 |
| Mckechnie William EdwardDirector | Jul 29, 2025 | Buy | 5,000 | $0.91 |
| Docherty John MartinOfficer — President & CSO | Jul 29, 2025 | Buy | 5,376 | $0.93 |
| Carle VanessaOfficer — Secretary | Jul 29, 2025 | Buy | 750 | $0.91 |
| Christopher RichardOfficer — Chief Executive Officer | Jul 29, 2025 | Buy | 15,000 | $0.91 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeFeb 6, 2026
- Shareholder voteJan 28, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventDec 16, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventSep 29, 2025
- Terminated a material agreementSep 25, 2025
- Entered a material agreementJun 12, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventApr 28, 2025
- Entered a material agreementFeb 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QApr 13, 2026
- 4PRIMARY DOCUMENTMar 18, 2026
- 8-KFORM 8-KFeb 6, 2026
- 8-KFORM 8-KJan 28, 2026
- S-8FORM S-8Jan 28, 2026
- EFFECTJan 14, 2026
- 424B3Jan 14, 2026
- 25-NSEJan 14, 2026
- 10-QFORM 10-QJan 13, 2026
- S-3FORM S-1Dec 29, 2025
- DDec 19, 2025
- 8-KFORM 8-KDec 16, 2025
- 424B5Dec 16, 2025
- DEF 14AFORM DEF 14ADec 10, 2025
- EFFECTDec 9, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.